Investigating lymph node patterns in lung adenocarcinoma
Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma - a Retrospective Cohort Study
Fudan University · NCT06745830
This study looks at how different patterns in lymph nodes from lung adenocarcinoma patients can help predict their health outcomes after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2998 (estimated) |
| Sex | All |
| Sponsor | Fudan University (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06745830 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic significance of pathologic patterns in metastatic lymph nodes (mLNs) of patients with lung adenocarcinoma. By analyzing a retrospective cohort of patients who underwent surgical resection, the study seeks to determine how the percentage of high-grade patterns in mLNs correlates with patient outcomes. The research focuses on understanding the implications of various histologic patterns in mLNs and their potential impact on prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with invasive lung adenocarcinoma who have undergone surgical resection.
Not a fit: Patients with adenocarcinoma in situ, minimally invasive adenocarcinoma, or other variants of adenocarcinoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of lung adenocarcinoma prognosis and improve patient management strategies.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have explored the prognostic value of lymph node patterns in various cancers, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: From January 2011 to September 2021, we consecutively collected patients with invasive LUAD who underwent surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center. Exclusion Criteria: 1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma; 2. incomplete common driver mutation data; 3. unavailable pathologic slides.
Where this trial is running
Shanghai, Shanghai Municipality
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Zhu
- Email: 20301050177@fudan.edu.cn
- Phone: 13301970795
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Adenocarcinoma